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the medical records of the enrolled patients, prescriptions were analyzed. Relevant
patient information such as gender, age, and data concerning psychotropic pre-
scribing patterns such as type of medication, route of administration, dose and
frequency were collected and evaluated for prescription patterns and associated
pharmaceutical care. RESULTS: Among the 60 bipolar patients enrolled during the
study period from January 2011 to April 2011, majority of the patients (78.3%) were
prescribed with antipsychotics, with olanzapine (25%) and resperidone (23.3%) be-
ing the two most common drugs followed by sedatives (73.3%), with clonazepam
(38.3%) being the most common drug. A total of 68.3% of patients were prescribed
with Lithium as the most common mood stabilizer. Among the patients (43.3%)
prescribed with antidepressants, the combination of fluoxetin and amitriptyline
was most common (23.3%) followed by fluoxetin alone (11.6%).Only 9 patients (15%)
were prescribed with divalproex sodium, an anticonvulsant. CONCLUSIONS: This
study showed that antipsychotics and sedatives were the two most commonly
prescribed drugs in bipolar patients with lithium being the most widely prescribed
mood stabilizer. The quality of pharmaceutical care is highly variable among pa-
tients with bipolar disorders, even in a specialty treatment setting.
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OBJECTIVES: The aim of the study is to investigate the use of medications pre-
scribed to dementia patients in a secondary care hospital METHODS: A retrospec-
tive chart review method was performed in patients with diagnosis of dementia for
the duration of six months. The relevant information related to the study objec-
tives such as demographic details, type of medication, dose and frequency etc has
been collected. The patient who has come for follow up during the study period has
also been included to find out any outcomes RESULTS: Out of 30 patients included
in the study, 63.3% were females and 36.7% were males. Most of the patients belong
to the age group of 60-80 years. On prescription pattern analysis, it was found that
86.7% of the patients were on donepezil, cholinesterase inhibitors. Among antip-
sychotics Quetiapine was the most commonly used atypical antipsychotic. Five
(16.7%) patients were on memantine where as 4 (13.3%) patients were on combi-
nation of donepezil and memantine. On follow up it was found that in three pa-
tients who was on donepezil has been changed to a combination of donepezil and
memantine. Whereas in other two patients the dose of the donepezil has been
increased. As a result of improvement seen in two patients donepezil was stopped
and memantine was continued and in the other patient who has been on the
combination of donepezil and memantine has been tapered gradually and stopped
as there was a marked improvement seen. In this study, we could also find pre-
scription error in 13.33% (4) of the prescription related to the overdose of donepezil
CONCLUSIONS: In a developing country like India, dementia still remains as an
underrecognized public health burden. Our study depicts a picture of usage of
antidementia drugs, it shows that further research to be done in dementia patients
related to cost effectiveness
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OBJECTIVES: Driven by rising costs of health care and concern that much of this
spending could be reduced without detriment to health, comparative effectiveness
research (CER) has been offered as a means to identify what works and does not
work in health care. Little conceptual and empirical efforts have been made, how-
ever, to quantitatively assess the impact of CER on health and health care spend-
ing. We interpret CER as infusing publicly subsidized evidence on product quality
into health care markets, shifting the relative demand for products in CER studies.
We analyze how these shifts in demand affect health and health care spending,
allowing for the possibility that “winners” of CER may be both more demanded by
patients and doctors as well as more favorably covered by payers. We also analyze
how CER may either raise or lower overall health when treatments have heteroge-
neous effects across patients, but payers respond with product-specific coverage
policies. METHODS: We calibrate the effects of product-specific coverage policies
for a major CER study for antipsychotics, the CATIE trial. RESULTS: We find that
such policies would have led to a decrease in overall health and value by inducing
some patients to switch away from treatments that were effective for them to-
wards winners of the CER. CONCLUSIONS: Our overall conclusion is that CER may
not always have the intended effects when the market responds to the CER and
patient specific effects of treatments are present.
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OBJECTIVES: German HTA-Agency (IQWIG) has published its preliminary report
plan for Order G09-01 Cost-benefit analysis of venlafaxine, duloxetine, bupropion
and mirtazapine in comparison to other prescription drug treatments (version 1.0,
updated 05-09-2011). This report plan provides important indicators, on how and to
what extent innovative drugs are to be reimbursed by German statutory health
insurances (SHI). METHODS: IQWIG conducts a cost-benefit analysis that can be
divided into five steps with main focus on Mixed Treatment Comparison (MTC).
The individual steps in the cost-benefit analysis are largely dependent upon one
another, since the results of one step serve as the foundation for the next step of
the analysis. It is critical to note that IQWIG compares the four individual antide-
pressants to active agent categories such as serotonin reuptake inhibitors (SSRIs),
without having previously conducted a benefit analysis for these active agent
groups. RESULTS: Preliminary report with the provisional assessments is expected
in the 3rd quarter of 2011. At present, essential information and specifications of
the methodical approach are still missing. Each of these steps yields considerable
methodological challenges and can significantly influence the results of the cost-
benefit analysis. The MTC method, in particular, must be transparently described.
Only in this manner, will it be possible to prevent uncertainties after every step
from adding up to an invalid overall result. CONCLUSIONS: When MTC do not
present relevant differences, or present them inadequately, this has significant
effects on the assessment of therapeutic superiority, as well as on the appropriate-
ness of the costs within the scope of the cost-benefit analysis. The result of such a
cost-benefit analysis would be that the benefits and additional benefits of new
drugs are levelled and the price level for modern antidepressants is decreased for
Germany in future.
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OBJECTIVES: To apply innovative methods to observational data to explore vari-
ability in depression scores over 12 years and examine whether there are subsets of
individuals with different trajectories of change. METHODS: Latent Growth Mod-
eling (LGM) and Growth Mixture Modeling (GMM) analyses were applied to obser-
vational data collected over a 12-year period. Data was obtained from the RAND
version of the Health and Retirement Survey (HRS), consisting of N 5090 individ-
uals aged 51 - 61 years at the time of recruitment. Scores on an 8-item version of the
Center for Epidemiological Studies–Depression Scale (CES-D) were examined.
LGMs were conducted to determine the level of variability in depression scores over
the 12-year period. When considerable variability was identified, GMMs were con-
ducted to assess whether there were subsets of individuals with differential
changes. RESULTS: LGMs showed an intercept (first assessment point) score of 0.75
(“no depression”) on the CES-D, which increased to 1.3 (“sub-threshold depres-
sion”) at year 12. Substantial variability was found around the mean intercept and
slope of change. GMMs identified three subsets of individuals with differential
slopes of change. The largest subset (83% of the sample) had a mean intercept of
0.22 and a 12-year score of 1.0 (“no depression”). A smaller subset (13.7%) had a
mean intercept of 2.5 and showed no change over the 12-year period (“stable,
sub-threshold depressed”). The smallest subset (3.3%) had a high mean intercept
(6.0) and showed a decrease in depression scores (4.0 at year 12; “improved, actively
depressed”). Post hoc analyses showed that these three classes were significantly
different in terms of gender, self-reported health, whether health limits their work
or activities, and activities of daily living CONCLUSIONS: Examining highly vari-
able data can yield insights about subsets of respondents who show different levels
of initial depression and different trajectories of change.
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OBJECTIVES: To compare the utility values estimated from a disease-specific in-
strument with those obtained from the EQ5D and SF6D in a sample of patients
suffering from a psychotic disorder. METHODS: Data on patients diagnosed with
schizophrenia or bipolar disorders was gathered in a multicentre, cross-sectional
study. Patients completed both generic and specific measures: the TooL question-
naire, EQ-5D -VAS and TTO-, SF6D and the Clinical Global Impression -CGI-SI-. As it
has been recently published, a multi-attribute utility function (MAUF) for the Span-
ish version of the TooL questionnaire was estimated. Differences in utility scores
regarding CGI-SI- were tested with ANOVA and Kruskal-Wallis test. The Spearman
correlation coefficient (rho), intraclass correlation coefficient and Wilcoxon rank
test were calculated. Finally, the Bland-Altman method was followed for concor-
dance assessment. RESULTS: In total, 37 patients with schizophrenia and 33 with
bipolar disorder were assessed. Mean age (SD) was 41.88 (11.08), 62.9% were male
and CGI-SI- was: borderline-mildly (50%), moderately (35.7%) and markedly-ex-
tremely ill (13.3%). Significant differences according to CGI-SI were found in all
utility measures (p0.05). Although all associations were high (rho range: 0.657-
0.996), differences between the TooL scores and generic scales (SF6D and EQ5D;
p0.001) were found. Also between EQ5D and SF6D remarkable differences were
found (p0.001). Generic measures tended to overestimate at least 80% of health
states in comparison to the TooL values. Finally, a low concordance was detected,
even between generic measures. CONCLUSIONS: Although all measures of health
values are highly associated, a low concordance has been evidenced. Utility values
obtained from the TooL questionnaire could be used to complement the informa-
tion from the EQ5D or SF6D. Finally, the specific measure could be even considered
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